ChemoCentryx Equity 2024

ChemoCentryx Aktienanalyse

What does ChemoCentryx do?

ChemoCentryx Inc. was founded in 1997 and is based in Mountain View, California. The company specializes in the development of medications for rare autoimmune diseases, cancer, and inflammation. Since its founding, ChemoCentryx Inc. has developed a variety of drug candidates, some of which are in clinical phases or as finished products. The business model of ChemoCentryx Inc. is based on the discovery and development of medications targeting chemokines and chemokine receptors. This technology allows for the regulation and control of inflammatory processes. The company also utilizes its proprietary Janus kinase inhibitors (JAK inhibitors) for the treatment of inflammatory diseases. ChemoCentryx Inc. has several business areas. The primary area is the research and development of medications that can be used as candidates against inflammatory, cancer, autoimmune, and fibrosis diseases. The second significant area is collaboration with international partners in the research and development of these medications. The company has also developed specialized tools and technologies to optimize its drug development processes. These techniques include high-throughput screening and X-ray crystallography technologies, as well as biomarker-based diagnostics. One important product of ChemoCentryx Inc. is Avacopan, an oral medication used in the treatment of ANCA-associated vasculitic diseases such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is a selective antagonist of the C5a receptor, which plays a central role in the inflammatory response. Clinical studies on the efficacy and safety of Avacopan have yielded promising results, and the medication has received Breakthrough Therapy Designation status from the US FDA. Additionally, ChemoCentryx Inc. has successfully identified candidates for the treatment of atopic dermatitis, lupus nephritis, and Crohn's disease. These products are still in the clinical development phase and have great potential to significantly improve the lives of patients suffering from these conditions. Overall, ChemoCentryx Inc. has made significant progress in the discovery and development of drugs that can combat inflammation and other chronic diseases. The company is well-positioned to expand its pipeline and bring additional breakthrough products to market that will play a crucial role in treating diseases that have been difficult to treat in the past. ChemoCentryx ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing ChemoCentryx's Equity

ChemoCentryx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ChemoCentryx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ChemoCentryx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ChemoCentryx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ChemoCentryx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ChemoCentryx stock

What is the equity of ChemoCentryx this year?

ChemoCentryx has equity of 286.12 M USD this year.

What was the equity of ChemoCentryx compared to the previous year?

The equity of ChemoCentryx has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of ChemoCentryx?

A high equity is advantageous for investors of ChemoCentryx as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of ChemoCentryx?

A low equity can be a risk for investors of ChemoCentryx, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of ChemoCentryx affect the company?

An increase in equity of ChemoCentryx can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of ChemoCentryx affect the company?

A reduction in equity of ChemoCentryx can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of ChemoCentryx?

Some factors that can affect the equity of ChemoCentryx include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of ChemoCentryx so important for investors?

The equity of ChemoCentryx is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can ChemoCentryx take to change the equity?

To change equity, ChemoCentryx can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does ChemoCentryx pay?

Over the past 12 months, ChemoCentryx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ChemoCentryx is expected to pay a dividend of 0 USD.

What is the dividend yield of ChemoCentryx?

The current dividend yield of ChemoCentryx is .

When does ChemoCentryx pay dividends?

ChemoCentryx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ChemoCentryx?

ChemoCentryx paid dividends every year for the past 0 years.

What is the dividend of ChemoCentryx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ChemoCentryx located?

ChemoCentryx is assigned to the 'Health' sector.

Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ChemoCentryx from 12/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did ChemoCentryx pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of ChemoCentryx in the year 2023?

In the year 2023, ChemoCentryx distributed 0 USD as dividends.

In which currency does ChemoCentryx pay out the dividend?

The dividends of ChemoCentryx are distributed in USD.